secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001558370-25-008922
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protalix shareholders elect eight directors, approve advisory compensation, ratify auditor at annual meeting
--------------------------------------------------------------------------------

- Eight director nominees elected with for votes ranging from 21.3M to 22.6M; broker non-votes ~12.7M.
- Non-binding advisory vote on named executive officer compensation passed: 16.4M for, 7.5M against, 0.4M abstain.
- Ratification of Kesselman & Kesselman (PwC Israel) as independent auditor for 2025 approved: 34.9M for, 1.6M against.
- Broker non-votes of ~12.7M present on director election and compensation proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025008922/0001558370-25-008922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025008922/plx-20250626x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer